title: [Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin].
abstract: Sixty-seven subjects with primary hypercholesterolemia were enrolled in an open study with "low dosages" of inhibitors of 3-hydroxy-3methylglutaril coenzyme A reductase. Patients were randomized in comparative and parallel study with simvastatin 10 mg (30 subjects) and pravastatin 20 mg (27 subjects) once in the evening for a treatment period of 12 months. At the end of the treatment the plasma concentrations of total and LDL cholesterol were reduced respectively by 21% (p < 0.001) and 29% (p < 0.001), plasma triglyceride concentration was reduced by 16%, high density lipoprotein (HDL) was increased by 2.9%. The efficacy of drugs was increasing during the study: at the third month 63% of subjects and at the twelfth month 89% of subjects showed a LDL < 160 mg/dL. In this study the drugs were well-tolerated, but 11 subjects showed a slight and transitory increase of CK. A treated group with simvastatin showed a similar decrease of the total cholesterol and LDL as that one treated with pravastatin. Pravastatin in comparison with simvastatin reduced significantly plasma triglycerides. There was no significant difference between the groups in the frequency of drug-related adverse effects. In conclusion "low dosages" of simvastatin and pravastatin in long term treatment were very efficacious in the reduction of total and LDL cholesterol. In our study, the decrease of total and LDL cholesterol was time-dependent, with the greatest reduction after sixth months. There were no significant differences between 10 mg of simvastatin and 20 mg of pravastatin on reduction of total and LDL cholesterol levels. Triglycerides decreased significantly only with pravastatin.
authors.affiliation: Centro Ipertensione Arteriosa e Medicina Vascolare, Ospedale Santa Chiara, Trento.
authors.forename: W
authors.initials: W
authors.lastname: Spagnolli
authors.forename: C
authors.initials: C
authors.lastname: Ramponi
authors.forename: C
authors.initials: C
authors.lastname: Focher
authors.forename: A
authors.initials: A
authors.lastname: Dal Piaz
authors.forename: P
authors.initials: P
authors.lastname: Torboli
authors.forename: R
authors.initials: R
authors.lastname: Miori
authors.forename: G
authors.initials: G
authors.lastname: De Venuto
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008148:Lovastatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage*; D012720:Severity of Illness Index; D019821:Simvastatin; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D000960:Hypolipidemic Agents; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin